Quantcast
Last updated on April 18, 2014 at 8:28 EDT

Latest Agendia Stories

2013-09-09 16:23:45

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, Calif. and AMSTERDAM, Sept. 9, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines confirmed that Agendia's MammaPrint(®) tests, the leading product in Agendia's Symphony suite of breast cancer tests, significantly augment prognostic and predictive information in making key cancer...

2013-08-27 08:26:32

'High Risk' Patients with Unusual Hormone Receptors May Be Undertreated IRVINE, Calif. and AMSTERDAM, Aug. 27, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset of breast cancer patients whose standard biomarker tests may incorrectly classify patients as "low risk" and benefitting from endocrine therapy. A study published this month in Breast Cancer Research and Treatment* concluded that this subset of...

2013-06-03 12:27:55

Veteran Diagnostics and Biotech Executive to Lead Global Commercialization IRVINE, Calif. and AMSTERDAM, June 3, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer. In this newly created position, Mr. Schineller will lead Agendia's global commercialization activities as it delivers technologies to translate personalized diagnostics into actionable, patient-centered solutions for...

2013-05-31 12:24:08

IRVINE, Calif., May 31, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall...

2012-11-27 12:29:35

IRVINE, Calif. and AMSTERDAM, Nov. 27, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types. The gene signature, discovered in collaboration with scientists from the Netherlands Cancer...

2012-09-13 02:28:30

AMSTERDAM and IRVINE, Calif., Sept. 13, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Clinical Oncology (ASCO) 2012 Breast Cancer Symposium. The meeting will be held from September 13-15, 2012 at the Marriott Marquis in San Francisco, California. Agendia's Symphony(TM) suite of molecular...

2012-08-29 10:23:21

IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular biologists. The...

2012-08-20 02:31:39

IRVINE, Calif. and AMSTERDAM, Aug. 20, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that it has been granted the International Organization for Standardization (ISO) 13485 certification for all activities at their facilities in Irvine and Amsterdam. Agendia has been a leader in maintaining the highest quality standards and operating in compliance with FDA GMP QSR, CLIA, CAP, OSHA and the CE Mark as well...

2012-08-09 02:29:58

IRVINE, Calif. and AMSTERDAM, Aug. 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Stefan Gluck, MD, PhD, will lead the company's Medical Advisory Board. As Chairman, Dr. Gluck is assembling a panel of leading medical oncologists, surgeons, scientists and pathologists to play a key role in advising Agendia on the clinical application of its extensive product pipeline, including its Symphony(TM)...

2012-07-09 02:25:06

IRVINE, Calif. and AMSTERDAM, July 9, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced a key addition to their executive team with the appointment of Glen Fredenberg as CFO and Vice President of Finance. "It is a very exciting time with the recent launch of Agendia's Symphony suite of tests in an FFPE format as well as the ColoPrint recurrence test for stage II colon cancer prognosis and prediction," said...